American Society of Hirudotherapy

Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial

Subgroup analysis of a randomized controlled trial published in Catheter Cardiovasc Interv (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialDrug DevelopmentClinical LiteratureWang H et al. · Catheter Cardiovasc Interv, 2017

Abstract

OBJECTIVES: To explore the efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access. BACKGROUND: Bivalirudin reduces bleeding risks over heparin in patients undergoing PCI. However, bleeding advantages of bivalirudin in patients undergoing transradial intervention is uncertain. METHODS: In the BRIGHT trial, 1,723 patients underwent emergency PCI via radial access, with 576 patients in the bivalirudin arm, 576 in the heparin arm and 571 in the heparin plus tirofiban arm. The primary outcome was 30-day net adverse clinical event (NACE), defined as a composite of major cardiac and cerebral events or any bleeding. RESULTS: 30-day NACE occurred in 5.7% with bivalirudin, 7.8% with heparin alone (vs. bivalirudin, P = 0.159), and 10.3% with heparin plus tifofiban (vs. bivalirudin, P = 0.004). The 30-day bleeding rate was 0.9% for bivalirudin, 2.3% for heparin (vs. bivalirudin, P = 0.057), and 5.8% for heparin plus tirofiban (vs. bivalirudin, P < 0.001). Major cardiac and cerebral events (4.9 vs. 5.7 vs. 4.6%, P = 0.899), stent thrombosis (0.5 vs. 0.5 vs. 0.7%, P = 0.899) and acquired thrombocytopenia (0.2 vs. 0.5 vs. 0.9%, P = 0.257) at 30 days were similar among three arms. The interaction test for PCI access and randomized treatment showed no significance on all bleeding (P > 0.05). CONCLUSIONS: The bleeding benefit of bivalirudin was independent of artery access. Bivalirudin lead to statistical reduction on bleeding risks in comparison to heparin plus tirofiban, and only small numerical difference in comparison to heparin, with comparable risks of ischemic events and stent thrombosis in patients with acute myocardial infarction (AMI) undergoing emergency transradial PCI. © 2016 Wiley Periodicals, Inc.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleMulticenter StudyRandomized Controlled Trial
Indexed MeSH termsAdolescentAdultAgedAged, 80 and overAnticoagulantsAntithrombinsCardiac CatheterizationChinaEmergenciesFemaleHemorrhageHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedNon-ST Elevated Myocardial InfarctionPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRadial ArteryRecombinant ProteinsRisk AssessmentRisk FactorsST Elevation Myocardial InfarctionTime FactorsTirofibanTreatment OutcomeTyrosineWarfarinYoung Adult

Summary

In this BRIGHT trial subgroup of 1,723 patients treated by transradial emergency PCI, bivalirudin significantly reduced 30-day bleeding versus heparin plus tirofiban (0.9% vs 5.8%), with comparable ischemic events and a benefit independent of access site.

Why This Matters for Hirudotherapy

The BRIGHT trial examined bivalirudin versus heparin or heparin plus tirofiban in 1,723 patients undergoing emergency percutaneous coronary intervention via radial access for acute myocardial infarction, with the primary outcome of 30-day net adverse clinical events (NACE). Bivalirudin showed a statistically significant reduction in 30-day bleeding compared with heparin plus tirofiban (0.9% vs. 5.8%, P < 0.001), while ischemic events, stent thrombosis, and thrombocytopenia were comparable across arms; the bleeding benefit was independent of artery access. This study is solely a pharmacological comparison of anticoagulant regimens in interventional cardiology. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Wang H, Li Y, Cong H, Ding S, Liu B, Li L, et al. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. Catheter Cardiovasc Interv. 2017;89(7):1157-1165. doi:10.1002/ccd.26804. PMID: 27677411

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.